Viking Therapeutics Stock Jumps as Obesity Drug Catalyst Nears
Viking Therapeutics shares rose sharply in Tuesday afternoon trading, climbing 6.0% to $34.30 as investors moved back into the clinical-stage biotech ahead of expected updates on its lead obesity-drug program. The Nasdaq-listed stock traded as high as $35.90 after opening at $31.76, with volume above 5.1 million shares.